May 26th 2023
New data indicates that increased risk for offspring in developing different disorders is associated with maternal alopecia areata exposure, expanding the available information on alopecia and maternal autoimmunity.
Surgeon General issues advisory regarding effects social media has on youths’ mental health
May 24th 2023Up to 95% of youth aged 13 to 17 years reported using a social media platform and more than a third said they use social media, “almost constantly,” according to a new advisory from the Surgeon General.
FDA approves adalimumab-adbm autoinjector pen for JIA, Crohn’s disease
May 22nd 2023Patients using adalimumab-adbm for chronic inflammatory disease treatment such as juvenile idiopathic arthritis (JIA), Crohn’s disease, and others, will have an autoinjector option beginning July 1, 2023, according to Boehringer Ingelheim.
How FDA-approved B-VEC will help children with dystrophic epidermolysis bullosa
May 20th 2023Following the FDA approval of beremagene geperpavec (B-VEC) (Vyjuvek; Krystal Biotech) to treat dystrophic epidermolysis bullosa (DEB) patients aged 6 months and older, Bernard A. Cohen, MD, discusses its safety and efficacy and how it can change the treatment landscape for DEB.
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older
May 19th 2023The FDA has approved Krystal Biotech's beremagene geperpavec (B-VEC) (Vyjuvek; Krystal Biotech) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients aged 6 months and older. B-VEC is the first FDA-approved gene therapy treatment for DEB, according to the agency. In this Contemporary Pediatrics interview, Raj Chovatiya, MD, PhD, breaks down this much-anticipated FDA approval.
Pfizer's infant RSV vaccine receives FDA Advisory Committee's support
May 19th 2023The FDA Advisory Committee recently voted in support of approval for Pfizer's maternal immunization vaccine to help prevent RSV in infants. In this Contemporary Pediatrics® interview, Tina Tan, MD, FAAP, FIDSA, FPIDS, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital, Chicago, explains what this means for this patient population ahead of an expected FDA decision in August, 2023.
Early screening can play a critical role in pediatric mental health
May 17th 2023Thomas R. Young, MD, discusses how important early screening is in children and adolescents with regard to mental health. He believes a reduction in stigma associated with mental health is occurring and that primary care professionals are encouraging youth to discuss what might be bothering them.
Tapinarof cream 1% demonstrates positive topline results for treating pediatric AD
May 16th 2023The once-daily topical cream for the treatment of atopic dermatitis (AD) has demonstrated positive topline results in 2 phase 3 studies in adults and children aged 2 years and up. According to Dermavant, a supplemental new drug application (sNDA) filed with the FDA is anticipated in Q1 of 2024.
FDA approves scoliosis correction system for pediatric idiopathic scoliosis
May 16th 2023The REFLECT Scoliosis Correction System from Globus Medical is intended to correct progressive scoliosis in pediatric patients while simultaneously maintaining stability and motion as well as allowing for future modulated growth.
Glucose levels are in target range at higher percentage with hybrid closed-loop system
May 16th 2023A hybrid closed-loop system can deliver glucose levels in the target range at a higher percentage of time among children aged 2 years to younger than 6 years compared to standard-care, according to a study in the New England Journal of Medicine.